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potential differences which should be considered when selecting data to answer 
specific research questions.
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Objectives: Real world evidence (RWE) is critical for the assessment of health 
technologies. This study was conducted to define and compare the governance 
of, and data sources available for, real world research (RWR) in Latin America (LA) 
and Canada. MethOds: Systematic literature review was conducted to exam-
ine administrative and clinical data for 10 major countries ranked by population. 
Research terms were defined by an international team, and reports were reviewed 
and assessed for content, quality and bias by two investigators. Data was sum-
marized in major and minor domains for each country. Results: Governance of 
RWR differed between countries, both from a regulatory and an ethics committee 
review perspective. Regulatory review was required for non-interventional studies 
in 4/10 countries. Ethics review varied importantly in complexity, site (local, cen-
tral) and duration (which could exceed 1 year). Administrative and clinical search 
terms returned over 1800 reports from LA, principally from Brazil, Mexico, Argentina 
and Chile, of which over 700 contained contributory information on data sources 
for RWE. Of these, 156 addressed international registries or databases including 
countries in LA, 245 reported national registries or databases within one country in 
LA, and 308 reported registries or databases from a single or multiple institutions 
within a country. Principal administrative categories included claims, prescription 
and economic data sources, while principal clinical categories included data sources 
relating to cancer, cardiology, neurology, respirology, and diabetes. In contrast, a 
total of over 2000 reports were obtained for Canada alone, with a similar categorical 
distribution to that observed in LA. cOnclusiOns: Latin America is a region with 
diverse health systems, inputs and outcomes. While sources for RWE exist in sev-
eral larger countries, comprehensive national or regional databases are uncommon 
compared with a mature public health care system such as Canada. Improvement 
of database quality and well-designed prospective population studies are critical 
to enhance the RWE base.
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bAckgROund: Real-world data are required to fully assess the value of treatments 
in clinical practice. Given the importance of having all available data to make this 
assessment, while ensuring efficiencies in preventing duplication of data collection, 
the absence of a central repository of longitudinal data sources on cancer patients 
in Europe remains a challenge. Objectives: i)Identify and characterize existing 
traditional and non-traditional data sources on lung cancer and renal cell carcinoma 
(RCC) patients in Europe; ii)Determine the utility of each identified data source 
for real-world research. MethOds: A systematic literature search was conducted 
using MEDLINE and Embase(01/01/06-20/12/13). MeSH and Emtree terms included 
the following concepts: lung cancer (small-cell and non-small-cell), RCC, real-world 
data (registry, cohort, etc), and European countries. Clinical trials, case reports, case 
series, literature reviews were excluded. Identified abstracts were screened and 
reviewed based on relevance to key concepts. For each data source, utility was 
assessed using the following variables: country, setting, type (e.g. registry, EMR, 
etc.), clinical and baseline characteristics, tumor, biomarkers, test results, treat-
ments, clinical and patient reported outcomes, resource utilization. Results: The 
search yielded 2,478 abstracts for lung cancer and 698 for RCC. Following screening, 
192(7.7%) and 102 (14.6%) were retained respectively. Data sources for lung cancer 
were equally distributed between general cancer and tumor specific registries. Most 
originated from the UK (33.3%) or France (13.8%). RCC data sources were primarily 
tumor specific and local with population size ranging from 56-1800. Data sources 
originated from Italy (22.5%), France, UK, and Germany (each 16.7%). Gap analyses 
with respect to the availability of specific data elements and utility for outcomes 
research will be presented. cOnclusiOns: Data sources on cancer are highly frag-
mented in Europe, especially for RCC, emphasizing the need for database mapping. 
Completeness and consistency of the data elements needed to support technology 
assessments are variable.
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Objectives: To establish quality of care benchmark estimates (HEDIS, PQA, or NQF) 
for Asthma, COPD, and Diabetes in the US Commercial Employer Sponsored Health 
Insured Population (EIS) for 2011. MethOds: The Marketscan Commercial claims 
database from 2010-2011 was used to identify the EIS population during 2011 and 
those patients with Asthma, COPD, and Diabetes. Patients needed at least 6 months 
of continuous coverage during 2011 and coverage during December 2011. Asthma, 
COPD, or Diabetes must have been recorded during 2011 or in the 6 months prior and 
was identified using a clinically approved coding algorithm. A weight was assigned 
Objectives: Capturing dosing of biologic and non-biologic Disease Modifying Anti-
Rheumatic Drugs (DMARDs) using electronic medical records is challenging. Precise 
estimates of weekly dose using structured pharmacy data alone are difficult since 
quantity dispensed is not standardized for injectable products. Natural Language 
Processing (NLP) software was developed to extract elements of the prescribing 
provider’s medication instructions (SIGs) to compute the average weekly dose. The 
objective was to evaluate the accuracy of the NLP software’s computation of the 
average weekly dose by medication and route. MethOds: The NLP software com-
puted the average weekly dose for biologic and non-biologic DMARDs and was 
evaluated against the annotator-derived reference standard. Using an annotation 
guideline, trained annotators annotated relevant information from SIGs including 
unit strength, dose per administration event and the schedule of administration 
events. The NLP software was then trained on 11,937 records. A validated set of the 
annotator-derived reference standard that contained 140 SIGs per medication and 
route was used to evaluate the NLP accuracy and compute the 95% Confidence 
Interval (CI) of accuracy. Results: The overall accuracy for injectable biologic and 
oral and injectable non-biologic DMARDs was 89.1% (95% CI: 87.9%-90.3%). Accuracy 
was 95.3% (95% CI: 91.9%-98.7%) for oral methotrexate, 84.7% (95% CI: 78.9%-90.5%) 
for injectable methotrexate, 87.9% (95% CI: 82.5%-93.3%) for sulfasalazine, and 92.9% 
(95% CI: 88.7%-97.2%) for hydroxychloroquine. For biologics, accuracy was 92.1% 
(95% CI: 87.6%-96.6%) for etanercept, 98.6% (95% CI: 96.7%-100%) for adalimumab 
and injectable abatacept 90.0% (95% CI: 85.2%-94.8%). The lower bound of the 95% CI 
ranged from 79.1%-100% for biologic DMARDs and from 78.9%-91.9% for non-biologic 
DMARDs. cOnclusiOns: The lower bounds of the 95% CI for most medications 
were greater than 80%. These results indicate that the NLP software can be used to 
extract information to calculate the weekly dose of DMARDs from narrative medi-
cation schedules.
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Objectives: Private claims databases have been a rich source of information related 
to health care delivery, though the fragmented nature of U.S. health insurance 
market limits their ability to provide a comprehensive view of a given geography. 
Additionally, claims data are often expensive (> $25,000) - restricting access to those 
with the economic means to afford it. To provide a more thorough view of health 
costs and practice at the state level, 11 states have created all payer claims databases 
(APCDs). An analysis was conducted to review their designs and consider how they 
will impact health economic analyses and health services research. MethOds: 
A detailed review of 11 APCDs was conducted using a combination of secondary 
research and key informant interviews. This included reviewing the legislation that 
mandated and funded their creation, the rules under which they operate, and the 
data they collect and make available. The multi-state analysis was then informed 
by a deeper analysis of the data integration opportunities, reporting abilities, and 
costs for data exchange for Maine’s newly revised APCD. Results: Across states, 
APCDs make publicly available a wide array of health data in a manner that ensures 
privacy and security of personal health information. Each APCD provides varying 
levels of granularity in health care resource utilization, demographic comparisons, 
expenditures, and quality/safety data. Ability to customize data pulls is growing, 
though private claims datasets appear to have greater flexibility. In Maine’s APCD, 
commercial and Medicaid medical, pharmacy, and dental data are available to 
researchers, with quarterly block releases and opportunities for individual que-
ries. cOnclusiOns: APCDs are providing researchers with an open-access, afford-
able pathway to understand health care resource utilization and practice across 
entire populations. As more come online, greater participation in health economic 
and health services research can be expected.
PRM42
building a Real-woRld non-sMall cell lung canceR cohoRt by 
linking a claiMs database to oncology electRonic Medical RecoRds
Chen C.C.1, Wade R.L.2, Khan N.1, Pokras S.M.3, Semonelli C.1, Zeng S.1, Marcus M.1
1IMS Health, Plymouth Meeting, PA, USA, 2IMS Health, Parsippany, NJ, USA, 3IMS Health, 
Alexandria, VA, USA
Objectives: Lung cancer (LC) leads cancer-related mortality in the U.S.; often 
diagnosed at an advanced stage with poor prognosis. Non-small cell lung cancer 
(NSCLC) accounts for approximately 85% of all LC. Real-world research in NSCLC 
necessitates clinical and longitudinal detail typically unavailable from any single 
retrospective data source. This study describes and benchmarks a comprehensive 
disease record for NSCLC patients created by linking the PharMetrics Plus (PMTX) 
database to an oncology electronic medical records (OEMR) database. MethOds: 
Adult NSCLC patients (ICD-9-CM code 162.2 to 162.9) with either confirmed histol-
ogy, use of pemetrexed, or without evidence of etoposide use were identified from 
PMTX and OEMR databases between 1/1/2006 and 7/31/2013. Patients were linked 
using a HIPAA-compliant encryption algorithm. Key patient characteristics from the 
linked sample were compared with the National Cancer Institute SEER registries 
NSCLC population (2006-2010, n= 152,465). Results: 182,425 NSCLC patients were 
identified (PMTX:156,029; OEMR:26,906), with 510 patients linked to both databases. 
Among linked patients, 50% were female, 36% were considered non-squamous (con-
firmed by histology or use of pemetrexed) and 47% were metastatic at diagnosis. 
Treatment data (surgical resection, radiation, or chemo/biological therapy) were 
available for 97% of the linked patients; 64% with platinum and 30% with pem-
etrexed therapy. The SEER population had a higher proportion of patients > = 65 
years at diagnosis (64% vs. 25%) but a lower portion (21%) metastatic at diagnosis 
compared to the linked sample. cOnclusiOns: This study demonstrates that data-
bases can be linked to provide a longitudinal, clinically rich view of an NSCLC popu-
lation. Comparisons between the linked sample and the SEER population highlight 
